Invivyd (IVVD) Other Non-Current Assets (2021 - 2025)
Invivyd posted quarterly Other Non-Current Assets of $110000.0 for Q4 2025, up 223.53% year-on-year from $34000.0 in Q4 2024, and up 1733.33% on a QoQ basis from $6000.0 in Q3 2025.
Invivyd (IVVD) has 5 years of Other Non-Current Assets data on file, last reported at $110000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets rose 223.53% year-over-year to $110000.0; the trailing twelve-month figure through Dec 2025 stood at $110000.0 (up 223.53% YoY), and the FY2025 full-year result was $110000.0, up 223.53% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $110000.0, up from $6000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $7.5 million in Q3 2024 and bottomed at $6000.0 in Q3 2025.
- The 5-year median for Other Non-Current Assets is $236500.0 (2022), against an average of $1.3 million.
- The widest annual swing landed in 2024, when Other Non-Current Assets surged 3885.03%; it then plunged 99.92% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $3.3 million in 2021, then plunged by 94.21% to $191000.0 in 2022, then declined by 8.38% to $175000.0 in 2023, then plunged by 80.57% to $34000.0 in 2024, then surged by 223.53% to $110000.0 in 2025.
- The last three Other Non-Current Assets figures came in at $110000.0 (Q4 2025), $6000.0 (Q3 2025), and $15000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | 110,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Sep 30, 2024 | 7.45 Mn |
| Jun 30, 2024 | 1.78 Mn |
| Mar 31, 2024 | 1.86 Mn |
| Dec 31, 2023 | 175,000.00 |
| Sep 30, 2023 | 187,000.00 |
| Jun 30, 2023 | 291,000.00 |
| Mar 31, 2023 | 291,000.00 |
| Dec 31, 2022 | 191,000.00 |
| Sep 30, 2022 | 236,000.00 |
| Jun 30, 2022 | 299,000.00 |
| Mar 31, 2022 | 237,000.00 |
| Dec 31, 2021 | 3.30 Mn |
| Sep 30, 2021 | 6.12 Mn |